Coherus Oncology (CHRS) Gross Profit Growth (3y) (2022 - 2026)

Coherus Oncology (CHRS) Gross Profit Growth (3y) (2022 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Gross Profit Growth (3y) (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn 54.36%
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn 7.16%
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn 3.86%
7 Belite Bio 61.40 Bn 61.40 Bn - -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn 80.64%
9 Revolution Medicines 37.37 Bn 37.37 Bn - -
10 Coherus Oncology 194.37 Mn 27.32 Mn 8.50 Mn -18.27%

Historic Data

Download Data
DateValue
Mar 31, 2026 -18.27%
Dec 31, 2025 -34.63%
Sep 30, 2025 -8.33%
Jun 30, 2025 -48.03%
Mar 31, 2025 -53.98%
Dec 31, 2024 -56.67%
Sep 30, 2024 -62.14%
Jun 30, 2024 -50.73%
Mar 31, 2024 -77.42%
Dec 31, 2023 -58.70%
Sep 30, 2023 -26.29%
Jun 30, 2023 -35.38%
Mar 31, 2023 -47.79%
Dec 31, 2022 -35.50%
Sep 30, 2022 -54.08%
Jun 30, 2022 -16.13%
Mar 31, 2022 13.32%